Volanesorsen for treating familial chylomicronaemia syndrome

life. Adverse events 4.16 The committee discussed the adverse events reported in the 2 main clinical trials. Common events (occurring in between 1 in 100 or more and fewer than 1 in 10 patients) in APPROACH were wide ranging, but the most frequent (in 1 in 10 or more patients) were limited to injection site reactions, fatigue, headache and thrombocytopenia. Seven (21%) patients in the volanesorsen group had serious adverse events compared with 5 (15%) patients on placebo. The committee recalled that safety risks had been identified with volanesorsen (see section 3.3), and an intensified routine monitoring scheme had been implemented in clinical trials and the EAMS. It noted, however, that the effect of volanesorsen on safety outcomes and, consequently of stopping treatment, was uncertain at the licensed dose in the long term. Cost to the NHS and value for money Company's economic model 4.17 The company presented an economic model comparing volanesorsen alongside a low-fat diet with standard care. The model had 2 components: a 3-month decision tree model and a long-term Markov model. In each 3-month model cycle, patients moved between TG bands or remained in the same band, had AP, developed chronic pancreatitis or died. Patients with
